

Ao Peng PhD

Head of Clinical Pharmacology and Early Clinical Development Strategy

Development China / Global Product Development

Pfizer

June 18, 2021



## Our vision for global clinical trials and our development goal in China

We ensure our global clinical trials reflect the demographics of the countries and communities
where we conduct these studies, and the epidemiology of the diseases we intend to treat or
prevent (我们确保开展的全球临床试验能够反映出所在国家和地区的人口学特征,以及目标治疗或
预防疾病的流行病学特征)

• Our development goal in China is to join the global clinical trials in both exploratory and confirmatory stages and ensure the simultaneous regulatory approval in China (我们在中国的研发目标是加入探索阶段和确证阶段的全球临床试验,以确保在中国的同步批准)



## The Challenges we are facing to join global clinical trials, especially in the exploratory phase

China Phase I study required prior to join global clinical trials
加入全球临床试验前,要求完成中国I期试验
Longer cycle time to initiate a clinical trial in China
临床试验启动时间长

VS

Short duration of expletory phase clinical trials 探索期临床试验的周期较短

Biomarker data and fast turnaround of data generation/transfer to support the PK/PD and E/R analyses 用于支持PK/PD和E/R分析的生物标志物数据,以及数据生成和传输的及时性

**VS** 

HGRAC approval 中国人类遗传资源管理批准

Our proposal for simultaneous global development in China - E17 based

Design and conduct confirmatory trials based

O: Where is Chinase and Jane Q: Where is Chinese and Japanese on a E/R based scientific pooling strategy located in the E/R curve China +Japan + more? 中国和和日本受试者E/R与总体人群的 基于科学的E/R分析,定义亚组人群合并策略,设计 相似性 和开展确证性临床试验 b) Responses on Responses on the primary the primary endpoint endpoint 2. Global strategy: representative example of MRCTs Region II Region II Submission\* Overall Overall Region I Region I Regulatory Exploratory A region Review clinical trials \*\* Multi Regional Including RegionII Region Confirmatory Submission\* Region II Region I pharmacology Group B Group D Clinical Trials Group C (PK/PD) study B region Regulatory mild Moderate Severe Ethnic group Review Severity of disease No delay Figure 2. Illustration: primary endpoint modulated by intrinsic and extrinsic factors across regions; (2a) by severity of disease, (2b) by ethnic group. **Analyze E/R including Chinese** China and Japan to join the and Japanese subjects exploratory clinical trials 包括中国和日本受试者数据在内 中国和日本加入探索期临床试验 的E/R分析 Global Product Development - Development China

## Thank You



